BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 22, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Biomarkers

FGF5 gene involved in excessive hair growth

Oct. 22, 2025
No Comments
Hirsutism is the excessive hair growth in women in male-typical areas, usually associated with androgen excess and other conditions such as polycystic ovary syndrome (PCOS). The genetic basis of hirsutism remains poorly understood; researchers from the University of Oulu and collaborators performed a meta-analysis of genome-wide association studies from 4,834 cases of hirsutism and 352,966 controls across three cohorts.
Read More
Drug R&D concept image.
Cancer

IND open for Dewpoint’s condensate modulator DPTX-3186

Oct. 22, 2025
No Comments
Dewpoint Therapeutics Inc. has announced an IND in the U.S. for DPTX-3186, a first-in-class oral condensate modulator designed to selectively disrupt oncogenic Wnt/β-catenin signaling in tumors. Dosing is set to begin before year-end in a phase I/II trial conducted in partnership with cancer centers and opinion leaders in gastric and other Wnt-driven cancers.
Read More
3D pancreas illustration
Cancer

Study reports insights into pancreatic cancer cell fate regulation

Oct. 22, 2025
No Comments

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer, with a 5-year relative survival rate of only 13%. To understand cell fate decisions and progression in PDAC, it is crucial to clarify the communication networks between tumor cells.


Read More
Art concept for epigenetic editing
Drug design, drug delivery & technologies

Epigenetic switch and gene editing activate human T cells

Oct. 22, 2025
By Mar de Miguel
No Comments
Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the University of California San Francisco (UCSF) have stably silenced or activated genes in this type of immune cell without cutting or altering its DNA, making T cells more resistant, active, and effective against tumors.
Read More
Dermatologic

Genescience Pharmaceuticals reports TYR inhibitors

Oct. 21, 2025
Genescience Pharmaceuticals Co. Ltd. has discovered new tyrosinase (TYR) inhibitors acting as melanin inhibitors potentially useful for the treatment of skin hyperpigmentation.
Read More
Gastrointestinal

Daewon Pharm patent reveals new H+/K+-ATPase inhibitors

Oct. 21, 2025
Daewon Pharmaceutical Co. Ltd. has reported new compounds acting as H+/K+-ATPase inhibitors useful for the treatment of reflux esophagitis.
Read More
Cancer

AKT1 inhibitors disclosed in Alterome Therapeutics patent

Oct. 21, 2025
Alterome Therapeutics Inc. has identified new RAC-α serine/threonine-protein kinase (AKT1; PKB-α) E17K mutant)inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Onkure Therapeutics patents PI3K inhibitors

Oct. 21, 2025
Onkure Therapeutics Inc. has disclosed new phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and scoliosis (CLOVES syndrome) and PIK3CA-related overgrowth spectrum.
Read More
Illustration of cancer tumor
Cancer

Next-generation inhibitors of PDGFR-α in cancer

Oct. 21, 2025
No Comments
Excessive signaling by platelet-derived growth factor receptor (PDGFR)-α, a transmembrane tyrosine kinase, helps drive the rapid angiogenesis that many types of tumor cells need in order to proliferate and metastasize.
Read More
Brain with handshake and cityscape
Neurology/psychiatric

Lundbeck and Contera Pharma partner in neurological disorders

Oct. 21, 2025
No Comments
H. Lundbeck A/S and Contera Pharma A/S have entered into a strategic research collaboration designed to accelerate the discovery and development of innovative oligonucleotide-based medicines for serious neurological conditions with unmet needs.
Read More
Previous 1 2 … 223 224 225 226 227 228 229 230 231 … 18104 18105 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • Alicorn synthesizes new AAK1 inhibitors

    BioWorld Science
    Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing